Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Want more breaking news
Patients should also contact their provider promptly if they experience: Persistent or worsening nausea and vomiting lasting more than a few days Inability to maintain adequate oral intake of food or fluids Symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat), particularly if taking tirzepatide with insulin or sulfonylureas Signs of allergic reaction, including rash, itching, swelling, or difficulty breathing Changes in vision or symptoms of diabetic retinopathy progression, especially with rapid improvement in blood glucose New lump or swelling in the neck, hoarseness, or difficulty swallowing (potential thyroid tumor symptoms) Routine follow-up should address less urgent concerns such as persistent mild nausea affecting quality of life, ongoing constipation or diarrhea, injection site reactions that don't resolve, or questions about dose adjustment
Accurate assessment of BC in patients with severe obesity is particularly critical, as it provides essential insights into physiological alterations that are not evident through conventional anthropometric measures
Approximately 3% of the absorbed dose is excreted in the urine as intact semaglutide
The interactive dosing schedule chart above shows the full week-by-week progression for both Zepbound (weight management) and Mounjaro (type 2 diabetes)
US$ 29.65
US$ 21.99
US$ 22.99
US$ 21.32
